Biomerieux Sa Stock Fundamentals
| BIM Stock | EUR 98.05 0.65 0.66% |
Biomerieux SA fundamentals help investors to digest information that contributes to Biomerieux's financial success or failures. It also enables traders to predict the movement of Biomerieux Stock. The fundamental analysis module provides a way to measure Biomerieux's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomerieux stock.
Biomerieux |
Biomerieux SA Company Operating Margin Analysis
Biomerieux's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Biomerieux Operating Margin | 0.21 % |
Most of Biomerieux's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomerieux SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Biomerieux SA has an Operating Margin of 0.2145%. This is 100.61% lower than that of the Healthcare sector and 100.34% lower than that of the Diagnostics & Research industry. The operating margin for all France stocks is 103.89% lower than that of the firm.
Biomerieux SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biomerieux's current stock value. Our valuation model uses many indicators to compare Biomerieux value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomerieux competition to find correlations between indicators driving Biomerieux's intrinsic value. More Info.Biomerieux SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.58 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biomerieux SA is roughly 1.74 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biomerieux by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biomerieux's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Biomerieux Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomerieux's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomerieux could also be used in its relative valuation, which is a method of valuing Biomerieux by comparing valuation metrics of similar companies.Biomerieux is currently under evaluation in operating margin category among its peers.
Biomerieux Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.4 B | |||
| Shares Outstanding | 118.37 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 18.57 % | |||
| Price To Earning | 35.41 X | |||
| Price To Book | 3.27 X | |||
| Price To Sales | 3.28 X | |||
| Revenue | 3.38 B | |||
| Gross Profit | 1.96 B | |||
| EBITDA | 1.01 B | |||
| Net Income | 601.1 M | |||
| Cash And Equivalents | 280.1 M | |||
| Cash Per Share | 2.38 X | |||
| Total Debt | 362.8 M | |||
| Debt To Equity | 27.30 % | |||
| Current Ratio | 1.71 X | |||
| Book Value Per Share | 29.31 X | |||
| Cash Flow From Operations | 811.1 M | |||
| Earnings Per Share | 4.66 X | |||
| Price To Earnings To Growth | 2.90 X | |||
| Target Price | 107.8 | |||
| Number Of Employees | 12.08 K | |||
| Beta | 0.16 | |||
| Market Capitalization | 11.04 B | |||
| Total Asset | 4.62 B | |||
| Retained Earnings | 949 M | |||
| Working Capital | 407 M | |||
| Current Asset | 1.1 B | |||
| Current Liabilities | 689 M | |||
| Z Score | 18.0 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 0.74 % | |||
| Net Asset | 4.62 B | |||
| Last Dividend Paid | 0.85 |
About Biomerieux Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomerieux SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomerieux using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomerieux SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.bioMrieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company was formerly known as B-D Mrieux. bioMrieux S.A. was founded in 1963 and is based in Marcy lEtoile, France. bioMrieux S.A. is a subsidiary of Institut Mrieux SA. BIOMERIEUX operates under Diagnostics Research classification in France and is traded on Paris Stock Exchange. It employs 11200 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biomerieux Stock
Biomerieux financial ratios help investors to determine whether Biomerieux Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biomerieux with respect to the benefits of owning Biomerieux security.